carboplatin,durvalumab,paclitaxel,olaparib,bevacizumab
astrazeneca,merck,roche
['durva', 'duo-o', 'ovarian', 'brca', ' ola ']
addition of io ( durva) to ovarian cancer treatment along with ola maintenance. duo-o trial. pfs hr - 0.49 for hrd postive. ( non brca mutated) o.63 in in itt . io won't work much in ovarian ca. modest benifits . is ovarian cancer treatment becoming too much loaded ? 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists